-
1 week ago | 
mdedge.com | Megan Brooks
An artificial intelligence (AI)–enhanced digital collaborative care model led to rapid, clinically significant, and sustained symptom relief for patients with i
-
1 month ago | 
medscape.com | Megan Brooks
The US Food and Drug Administration (FDA) approved guselkumab (Tremfya, Johnson & Johnson) for the treatment of adults with moderately to severely active Crohn’s disease (CD). The approval marks the fourth indication for guselkumab, which was approved for moderate to severe plaque psoriasis in 2017, active psoriatic arthritis in 2020, and moderately to severely active ulcerative colitis in 2024.
-
1 month ago | 
mdedge.com | Megan Brooks
FROM SGO 2025Results from the PHENIX-I trial support skipping pelvic lymphadenectomy in women with early cervical cancer who have a negative sentinel lymph node biopsy. Omitting pelvic lymphadenectomy in these patients “did not compromise disease-free survival and potentially [led to] improved overall survival,” reported lead investigator Jihong Liu, MD, gynecologic oncologist, Sun Yat-sen University Cancer Center, Guangzhou, China.
-
1 month ago | 
medscape.com | Megan Brooks
The American College of Gastroenterology (ACG) has issued its first clinical practice guideline on the diagnosis and management of gastric premalignant conditions (GPMCs) including atrophic gastritis, gastric intestinal metaplasia, dysplasia, and certain gastric epithelial polyps, all of which have an increased risk of progressing to gastric cancer. The guideline was published online on March 12 in The American Journal of Gastroenterology.
-
2 months ago | 
medscape.com | Megan Brooks
Antidepressants, particularly selective serotonin reuptake (SSR) inhibitors, were associated with significantly faster cognitive decline in individuals with dementia, results of a real-world national cohort study showed. However, the investigators caution that the clinical significance of the observed changes are uncertain and the possibility that they are because of depression, rather than antidepressant use, can’t be ruled out.
-
2 months ago | 
mdedge.com | Megan Brooks
FROM CLINICAL GASTROENTEROLOGY AND HEPATOLOGYThe American Gastroenterological Association (AGA) has released an expert review and clinical practice update focusing on esophageal dysfunction caused by immune-mediated and infectious diseases. “Many different disorders can lead to esophageal dysfunction, which is characterized by symptoms including dysphagia, odynophagia, chest pain and heartburn.
-
Feb 7, 2025 | 
medscape.com | Megan Brooks
Treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide had no disease-modifying effects on movement, symptom severity or brain imaging in patients with Parkinson’s disease (PD) enrolled in a phase 3 trial.
-
Feb 5, 2025 | 
mdedge.com | Megan Brooks
The mental health consequences of COVID-19 deaths are likely to overwhelm an already tattered U.S. mental health system, leading to a lack of access, particularly for the most vulnerable, experts warn. “A second wave of devastation is imminent, attributable to mental health consequences of COVID-19,” write Naomi Simon, MD, and coauthors with the department of psychiatry, New York University. In a Viewpoint article published in JAMA on Oct. 12, physicians offer some sobering statistics.
-
Jan 28, 2025 | 
medscape.com | Megan Brooks
Heart disease remains the leading cause of death in the United States, fueled by ongoing increases in hypertension, obesity, and other major risk factors, according to the American Heart Association’s (AHA) 2025 Heart Disease and Stroke Statistics. Cardiovascular disease, which includes heart disease and stroke, claims more lives in the United States than all forms of cancer and accidental deaths — the number two and number three causes of death — combined.
-
Jan 28, 2025 | 
mdedge.com | Megan Brooks
Overtreatment of men with prostate cancer and limited life expectancy (LE) has persisted in the era of active surveillance and worsened in some instances, according to a new study of nearly 250,000 veterans. “Overtreatment of men with limited longevity for intermediate- and high-risk tumors has not only failed to improve but has actually worsened over the last 20 years,” Timothy Daskivich, MD, MSHPM, with Cedars-Sinai Medical Center, Los Angeles, said in an interview.
